Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Spravato (esketamine)
Marketing
Johnson & Johnson launches ‘Generation Fine’ depression project
You’ve heard of Gen Z, but now J&J wants you to be aware of “Generation Fine” as it looks to boost understanding around depression treatment.
Ben Adams
May 8, 2026 9:44am
J&J chief Joaquin Duato collects sizable pay raise for 2025
Mar 11, 2026 10:55am
FDA signs off on Johnson & Johnson's Spravato as a monotherapy
Jan 21, 2025 3:23pm
J&J expects 25 blockbuster drugs to drive future sales growth
Dec 5, 2023 4:42pm
J&J takes major hit from litigation cost in 2023's first quarter
Apr 18, 2023 11:15am
J&J builds case for Spravato in tough-to-treat depression
Nov 23, 2022 10:05am
